Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study

Scand J Urol Nephrol. 2003;37(3):213-7. doi: 10.1080/00365590310008073.

Abstract

Objective: To evaluate whether initial surveillance followed by prostatectomy impairs pathological stage compared to immediate surgery in men with prostate cancer detected as a result of early screening.

Material and methods: A total of 26 patients with prostate cancer [T1c-T2, Gleason score <7, prostate-specific antigen (PSA) 3-13 ng/ml] who were managed by means of initial surveillance (mean 23.4 months, range 8-55 months) followed by radical retropubic prostatectomy (RRP) were evaluated. For each of these cases two matched control cases were selected from patients who were operated on without prior surveillance. The two groups were matched for PSA, age, T stage and Gleason score at biopsy. Evaluation of prostatectomy specimens included measurement of tumour volume, pT stage and Gleason score.

Results: Tumour volume did not differ significantly between cases and controls: 1.35 vs 1.05 cm (3), respectively. The frequency of extracapsular growth, Gleason score and time to progression after RRP within a mean follow-up period of 2 years were also similar between the two groups.

Conclusion: In selected patients with very early prostate cancer it seems that close surveillance followed by prostatectomy when signs of progression appear is a low-risk option. However, before this strategy can be generally recommended longer follow-up periods should be used and a randomized study should be performed.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Biopsy, Needle
  • Follow-Up Studies
  • Humans
  • Male
  • Mass Screening / methods*
  • Middle Aged
  • Monitoring, Physiologic / methods
  • Neoplasm Staging
  • Observation
  • Probability
  • Prostate-Specific Antigen / blood*
  • Prostatectomy / methods*
  • Prostatectomy / mortality
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / surgery*
  • Reference Values
  • Risk Assessment
  • Statistics, Nonparametric
  • Survival Rate
  • Sweden
  • Time Factors
  • Treatment Outcome

Substances

  • Prostate-Specific Antigen